Filtered By:
Drug: Magnesium
Education: Learning
Management: Food and Drug Administration (FDA)
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 3 results found since Jan 2013.
3 reasons your child shouldn’t go “gluten-free” (unless your doctor says so)
Follow me at @drClaire
There is a puzzling and worrisome new phenomenon that I am seeing as a pediatrician: parents who are putting their children on gluten-free diets.
It’s puzzling because in the vast majority of cases it isn’t necessary — and it’s worrisome because, although parents are doing it because they think it’s healthy, a gluten-free diet can be very unhealthy for children.
Gluten is a protein found in wheat, rye, barley, and some other grains. It’s in bread and other baked goods, cereals, pastas — and in many other foods in small amounts. For people with celiac disease, even those small amounts ca...
Source: New Harvard Health Information - June 7, 2016 Category: Consumer Health News Authors: Claire McCarthy, MD Tags: Children's Health Healthy Eating Parenting Source Type: news
In the Raw: To Cook or Not to Cook?
Imagine never again savoring the smell of baking cakes or charbroiled steak.
Could you? Why would you?
Yet some people worldwide are turning away not only from meat and processed food, but also from cooking.
Welcome to the raw food diet.
As the Standard American Diet becomes more fat-laden, sugar-sated, and processed, the prevalence of metabolic disorders, obesity, type 2 diabetes, and cardiovascular disease (CVD) are soaring.
According to the Centers for Disease Control and Prevention (CDC), obesity now affects nearly 35 percent of the population of the United States, over 29 million people have been diagnosed with t...
Source: Healthy Living - The Huffington Post - August 4, 2016 Category: Consumer Health News Source Type: news
Janssen Announces U.S. FDA Approval of INVEGA HAFYERA ™(6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia
TITUSVILLE, N.J., Sept. 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic INVEGA HAFYERA™ (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults. Before transitioning to INVEGA HAFYERA™, patients must be adequately treated with INVEGA SUSTENNA® (1-month paliperidone palmitate) for at least four months, or INVEGA TRINZA® (3-month paliperidone palmitate) for at least one 3-month injection cycle.1 The FDA approval of INVEGA ...
Source: Johnson and Johnson - September 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
